Navigation Links
Oscar-Nominated True Grit Gets Top Reviews for Acting but Mixed Reviews for Snakebite Treatment

WEST CONSHOHOCKEN, Pa., Feb. 25, 2011 /PRNewswire/ -- Confronting a rattler may be a minor challenge for Rooster Cogburn in the Coen brothers' Oscar-nominated remake of True Grit, but proper handling of poor Mattie's snakebite was a major ordeal in the old West.  The tough-as-nails U.S. Marshall unknowingly perpetuates Hollywood myth by doing precisely the opposite of proper snakebite protocol, although the hero does get it right when it comes to the need for speed in seeking immediate treatment.

Cutting the skin ("X marks the spot") to suck or bleed out the poison, applying a tourniquet, bandage or pressure, and drinking alcohol not only don't help, but may cause added harm by further damaging tissue.

Despite all of the folklore, the only correct response to poisonous snakebite is to seek emergency care.  Remain calm and call 911 or your local poison control center at (800) 222-1222.  Snakebite treatment is best left to the experts! So it is imperative to get to an appropriate hospital or emergency center as quickly as possible.

Above all, do not attempt to capture the snake, which could very well result in a second bite. CroFab® Crotalidae Polyvalent Immune Fab (ovine) is an intravenous medicine, usually administered in the hospital emergency room, that is approved to treat venomous snakebites from North American pit vipers.  Pit viper snakes include rattlesnakes, copperheads and cottonmouths/water moccasins.  BTG International Inc. markets and distributes CroFab® to hospitals in the United States.

"Although nowadays we don't cut and suck snakebites like the cowboys used to do, Rooster knew the best thing for Mattie was to get her to a doctor as fast as he could," said Sean Bush, MD,  Professor of Emergency Medicine at Loma Linda School of Medicine in Loma Linda, CA.  "The same is true today.  The difference now is that there is a treatment to prevent the progression of a venomous pit viper bite."

About CroFab®

CroFab® Crotalidae Polyvalent Immune Fab (ovine) is an antivenom used for the management of patients with North American crotalid envenomation.  Crotalid snakes include rattlesnakes, copperheads and cottonmouths/water moccasins.  This antidote is appropriate for use in the great majority of U.S. snakebites, outside of the coral snake.  Early use of CroFab® (within 6 hours of snakebite) is advised to prevent a patient's clinical deterioration and the occurrence of systemic blood-clotting (coagulation) abnormalities.

Important Safety Information

The most common adverse events reported in clinical studies were mild or moderate reactions involving the skin and appendages (primarily urticaria, rash, or pruritus), which occurred in 14 out of 42 patients. Three patients experienced a serious adverse event. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment.  One patient had a recurrent coagulopathy due to envenomation, which required rehospitalization and additional antivenom administration.  In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenom), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied.  Recurrent coagulopathy may persist for 1 to 2 weeks or more.  One patient discontinued CroFab® therapy due to an allergic reaction.  Patients with allergies to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also be at risk for an allergic reaction to CroFab®.  

For CroFab® full prescribing information, visit:

About Poison Control Centers

The American Association of Poison Control Centers works to support the nation's 60 poison centers in the valuable work they do. America's poison centers are open 24 hours a day, 7 days a week to help you. The phone number 1-800-222-1222 will connect you to your local poison center anywhere in the United States. The call is free, confidential, and answered by medical professionals.

About BTG

BTG is an international specialist healthcare company that is developing and commercializing products targeting critical care, cancer and other disorders.  The company is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products. For further information, visit:

SOURCE BTG International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
2. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
3. Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
4. GSK Regulatory Update on Avandia Following EMA and FDA Reviews
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
7. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
8. Misonix Previews New OsteoSculpt® Ultrasonic Bone Scalpel
9. Obesity Organizations Call for a Full and Fair Hearing When the FDA Reviews New Treatments for Obesity
10. DK Sinopharma, Inc. Reviews its Honors of the Year 2010
11. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Post Your Comments:
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):